AB-101

AB-101 is our oral PD-L1 inhibitor.

The immune system of HBV chronically infected patients is tolerized to recognize the virus or infected cells. To achieve a functional cure and long-term HBV viral control, it is believed that highly functional HBV specific T-cells are required.

Immune checkpoints such as PD-1/PD-L1 play an important role in the induction and maintenance of immune tolerance and in T-cell activation.   

Clinical data to-date

AB-101 is currently in a Phase 1a/1b clinical trial that is evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single- and multiple-ascending oral doses of AB-101 in healthy subjects and patients with cHBV. In parts 1 and 2, which included the single- and multiple-ascending doses in healthy subjects, AB-101 was generally well-tolerated with evidence of receptor occupancy. AB-101 is currently being dosed in part 3 of this trial which includes patients with cHBV.